Roche’s Alecensa kept people with lung cancer alive longer than Pfizer’s Xalkori

News Hour:

Roche’s Alecensa kept people with a specific lung cancer alive longer without their disease progressing than Pfizer’s Xalkori, the Swiss drugmaker said on Monday, as it seeks to move in on the U.S. company’s share of early treatment of the disease. Roche now plans to submit the results of the Phase III study to global health regulators, it said in its statement.

Alecensa, approved since 2015 in people with advanced ALK-positive non-small cell lung cancer who have failed on Xalkori, is now being trialed head-to-head against Pfizer’s medication as an initial treatment, reports Reuters.

Avatar

This article has been posted by a News Hour Correspondent. For queries, please contact through [email protected]
No Comments

Translate this News

Join the Facebook Group

Click here to join the Facebook group of News Hour

Popular Posts

Sacred Games exposes Rajshri Deshpande nude [video]
Paperfly launches delivery services covering 64 districts in Bangladesh
The miracle of Hyperbaric Oxygen Therapy (HBOT) and its potential in Bangladesh
Shaon is not the only heir to Humayun Ahmed’s intellectual property: Nuhash Humayun
Eiza Gonzalez accidentally show Josh Duhamel Naked video on Instagram
Workshop to formulate nutrition action plan held in Nilphamari

Advertisement

News of the Month

April 2017
S M T W T F S
« Mar   May »
 1
2345678
9101112131415
16171819202122
23242526272829
30  
Scroll Up
%d bloggers like this: